三诺生物(300298) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for the reporting period reached ¥1,013,580,318.64, representing a 14.92% increase compared to ¥657,878,961.30 in the same period last year[51]. - The net profit attributable to shareholders of the listed company was ¥80,937,582.74, a 35.51% increase from ¥67,665,023.79 in the previous year[51]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥77,581,081.91, reflecting a 21.48% increase compared to ¥63,863,716.61 in the same period last year[51]. - The net profit for the current period is 91,621,188.01, a significant increase from 34,846,787.57 in the previous period, representing a growth of 162.5%[74]. - Operating profit reached 108,903,207.95, compared to 46,818,527.59 in the previous period, marking an increase of 132.5%[74]. - The total profit for the current period is 108,743,996.24, up 132.92% from 46,687,171.72 in the previous period, attributed to improved operations at Trividia Health Inc[85]. - The total comprehensive income for the current period is 56,750,444.70, compared to 14,343,742.03 in the previous period[74]. - The diluted earnings per share for the current period is 0.1457, up from 0.1072 in the previous period[74]. Assets and Liabilities - The total liabilities decreased from CNY 2,456,251,548.33 to CNY 2,307,888,057.35, a reduction of approximately 6.05%[22]. - The company's total assets decreased from CNY 5,926,971,817.35 to CNY 5,819,717,382.84, a decline of approximately 1.81%[22]. - The company's total assets at the end of the reporting period amounted to ¥5,819,717,382.84, a decrease of 1.81% from ¥4,528,738,427.47 at the end of the previous year[51]. - The company's total liabilities decreased from ¥2,200,000,000 to ¥2,100,000,000, indicating improved financial stability[100]. - The company's goodwill increased slightly from ¥1,120,176,081.80 to ¥1,121,412,972.88 during the reporting period[100]. - The company's deferred tax assets decreased from ¥111,524,097.20 to ¥106,056,211.66, reflecting changes in tax positions[100]. Cash Flow - Cash flow from operating activities showed a net outflow of ¥31,618,218.42, a significant decrease compared to a net inflow of ¥60,154,052.10 in the previous year, marking a 168.63% decline[51]. - The net cash flow from operating activities is -¥31,618,218.42, a decrease of 168.63% compared to ¥46,071,967.51 in the previous period[doc->59]. - The cash inflow from operating activities totaled 1,000,955,439.65, a decrease from 1,065,382,056.98 in the previous period[75]. - The cash flow from financing activities is -¥66,012,412.86, a decline of 135.08% from ¥188,152,964.66 in the previous period[doc->59]. - The impact of exchange rate fluctuations on cash and cash equivalents was -¥7,263,899.30, a significant decline compared to the previous period's gain of ¥1,248,127.24[doc->59]. Shareholder Information - The number of common shareholders at the end of the reporting period was 12,101, with the largest shareholder holding 25.29% of the shares[43]. - The company plans to repurchase shares using self-owned funds between ¥80 million and ¥150 million, with a maximum repurchase price of ¥35.00 per share[45]. - The company repurchased a total of 3,421,500 shares, accounting for 0.61% of the total share capital, with a total transaction amount of ¥84,972,866.00[doc->67]. - The company repurchased a total of 10,420,787 shares, accounting for 1.85% of the total share capital of 564,265,337 shares, with a total transaction amount of ¥253,558,050.23[91]. Research and Development - Research and development expenses for the current period are ¥95,585,949.49, an increase of 26.3% from ¥75,723,095.13 in the previous period[73]. - Research and development expenses increased by 26.23% to 95,585,949.49, primarily due to increased investment in CGM development[85]. Employee Stock Ownership Plan - The company plans to extend the deadline for its third employee stock ownership plan by 9 months to ensure its successful implementation[28]. - The company plans to implement a third employee stock ownership plan, with a maximum of 3 million shares to be acquired at a price of ¥25.69 per share[98]. - The first employee stock ownership plan has sold a total of 12,261,322 shares, accounting for approximately 2.17% of the company's total share capital[106]. - The employee stock ownership plan was strictly implemented in compliance with stock market trading rules and regulations[106]. - The first phase of the employee stock ownership plan has been completed and terminated as of January 15, 2024[106]. - The company disclosed the completion and termination of the employee stock ownership plan on January 17, 2024[106]. Other Financial Metrics - The weighted average return on net assets was 2.59%, an increase of 0.46 percentage points compared to 2.40% in the previous year[51]. - The cash received from investment returns increased by 2800.78% to ¥406,109.46 from ¥14,000.00 in the previous period[doc->59]. - The net cash flow from investing activities improved by 95.14%, resulting in -¥9,030,795.06 compared to -¥185,639,574.10 in the previous period[doc->59]. - The company reported a significant increase in other income, which rose to 199,641.90 from 3,242.16, reflecting a growth of 6057.68%[85]. - The company's cash and cash equivalents decreased by 100% due to the maturity of structured deposits from a subsidiary[36]. - The company's cash and cash equivalents at the end of the reporting period were ¥672,599,247.55, down from ¥786,037,973.76 at the beginning of the period[46]. - The company's cash and cash equivalents at the end of the first quarter of 2024 were ¥664,544,455.56, down from ¥700,353,249.17 at the end of the previous period[104]. - The company's short-term borrowings decreased significantly by 72.10%, from CNY 89,880,671.68 to CNY 25,075,466.32, primarily due to repayment of loans[36].